WEBULL
WebtradeDownload

Tarsus Pharmaceuticals (TARS) Stock May Trade At A Discount On Strong Sales Growth

Simply Wall St · 3d ago

Tarsus Pharmaceuticals has delivered a very strong 3 year share price run, yet the recent pullback and busy news flow now put the focus squarely on whether the current valuation is supported by the cash the business can generate. With a Discounted Cash Flow (DCF) view available, the key issue for investors is how the latest expectations around its products and pipeline stack up against the price on screen.

  • The stock is up about 333.1% over the past 3 years, which puts a lot of weight on the question of whether the underlying cash flows can keep justifying that kind of re-rating.
  • Record sales for XDEMVY, expanded marketing and new late stage programs may support expectations for stronger and more durable cash generation in the years ahead.
  • What if you looked at Tarsus Pharmaceuticals through its sales instead? See what Tarsus Pharmaceuticals's 4.9x P/S says about the price.

The issue now is whether the cash flows implied by the intrinsic value estimate line up with where Tarsus Pharmaceuticals trades today.

If you want to sanity check Tarsus Pharmaceuticals against other businesses where valuation is anchored in cash generation, consider broadening the view with 42 high quality undervalued stocks.

Is Tarsus Pharmaceuticals a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here estimates what Tarsus Pharmaceuticals might be worth based on the cash it can return to shareholders over time. Latest twelve month free cash flow sits at about $31.6 million, yet the model builds in a dip to a projected free cash flow loss of about $81.3 million in 2025 before moving back to positive territory over the following years. That path implies a recovering and then growing cash profile rather than a straight line ramp from today.

The long range inputs assume that free cash flow scales up gradually through the next decade, which needs to be weighed against a current share price of $67.44. Record XDEMVY sales and the expanded late stage pipeline reported in the recent Q3 2026 update help explain why the DCF output comes in substantially above where the market is pricing Tarsus Pharmaceuticals today. Find out what Tarsus Pharmaceuticals could be worth using our Discounted Cash Flow (DCF) estimate.

The Tarsus Pharmaceuticals Narrative: What Would Justify Today's Price?

Narratives on Simply Wall St pick up where the valuation question for Tarsus Pharmaceuticals leaves off and explain which assumptions about growth, margins and future earnings would need to hold for the stock to be worth materially more or materially less than today's price, on the Community page.

Each one treats Tarsus Pharmaceuticals' implied fair value as a thesis about the business that you can revisit over time rather than a static snapshot.

One of the top community narratives on Tarsus Pharmaceuticals: 42% undervalued

"The main factor that needs to go right is that XDEMVY maintains strong demand while ALK-001, IRX-101, TP-04 and TP-05 advance efficiently…"

Discover why this Narrative puts Tarsus Pharmaceuticals at 42% undervalued.

One more angle on Tarsus Pharmaceuticals that should not be skipped

Tarsus Pharmaceuticals has a detailed valuation story, yet the internal checks also highlight specific risk factors that deserve your attention before you lean too hard on any model output. Take a closer look at 2 warning signs before settling on a valuation.